{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/New-TALVEY-talquetamab-tgvs-plus-DARZALEX-FASPRO-daratumumab-and-hyaluronidase-fihj-data-demonstrate-the-strength-of-a-bispecific-combination-in-earlier-line-relapsed-or-refractory-multiple-myeloma/default.aspx", "message": "News view counter 798400 successfully enlarged"}